The elective backlog in 2026: a target met, a plateau, and an independent sector in the wrong places

At the end of August 2026 there were 7.37 million referral to treatment pathways on the waiting list in England. Because some people wait on more than one pathway, NHS England estimates that this is about 6.2 million individual patients. The list is 0.5% smaller than a year earlier. That flat headline hides two things that matter for anyone selling into NHS elective care: progress has stalled since the spring, and the independent sector is concentrated in specialties that are no longer where the worst waits are.

A target met, then held rather than beaten

The interim ambition for March 2026 was for 65% of patients to be waiting under 18 weeks. NHS England’s time series, which includes estimates for trusts that did not report, puts March 2026 at 65.3%. The target was met, narrowly.

Five months later the position has not improved. In August 2026, 65.2% of pathways were within 18 weeks. That is 4.2 percentage points better than August 2025, but no better than March. Over the same five months the list grew from 7.11 million to 7.37 million pathways, and the number waiting more than 52 weeks rose from about 94,400 to 113,339. The constitutional standard is still 92%.

The next step is harder. The Medium Term Planning Framework asks every trust to improve 18-week performance by at least 7%, or to reach 65%, whichever is greater, in 2026/27. The aim is a national figure of 70%, and 92% by the end of 2028/29. The activity mix makes that harder still. In the 12 months to August 2026, clock starts per working day rose 3.2% and completed pathways rose 2.2%. Completed admitted pathways actually fell 2.8%, while non-admitted pathways rose 3.5%. Growth is coming from outpatient work, not from operations.

Where the long waits sit

Trauma and orthopaedics has the largest list, with about 851,000 pathways at reporting trusts and 60.9% within 18 weeks. It also has the most long waiters: 22,043 pathways over 52 weeks. Trauma and orthopaedics, gynaecology and ENT together account for 43% of all 52-week waits at reporting trusts. Oral surgery has the weakest 18-week performance of any major specialty, at 53.8%.

The independent sector: concentrated, and capped

Our analysis of the August 2026 provider-level data shows that independent and other non-NHS providers delivered 17.5% of completed admitted pathways and 7.0% of non-admitted pathways. The admitted share is very uneven. It is 44.6% in ophthalmology and 30.8% in trauma and orthopaedics, but 6.0% in gynaecology and 2.2% in ENT.

That is the mismatch. The sector is deep in high-volume, standardised day-case work, where it built its NHS business. It is shallow in two of the three specialties that hold the most 52-week waits.

NHS volumes are also under pressure. The Independent Healthcare Providers Network (IHPN) reports that the sector’s share of NHS elective activity rose from about 7% before the pandemic to a peak of 10% in late 2024 and early 2025, then fell to 7.5% in February 2026. Its admitted activity that month was 22% lower than in February 2025. IHPN links the fall to integrated care boards (ICBs) using Activity Management Plans, which can put a hard cap on what a provider delivers. ICBs could use these from October 2025. IHPN also points to changes in how choice-based services are contracted. In April and May 2026, independent sector RTT activity was 9% lower than in the same months two years earlier. IHPN measures share differently from our provider cut, so the two series should not be compared directly. The direction is the same, though.

Speed is not the problem. In August 2026, 75.4% of pathways waiting with non-NHS providers were within 18 weeks, compared with 64.4% at NHS providers. Commissioners are trading speed for control of the elective budget, and that is shaping the market.

Diagnostics: the front door is the bottleneck

At the end of August 2026, 1.83 million people were waiting for one of the 15 key diagnostic tests. That is 149,300 more than a year earlier. Of these, 24.7% had waited six weeks or more. The standard is 1%, and the 2026/27 planning requirement is 20% or better, or an improvement of at least 3%. Tests performed rose to 2.51 million in the month.

Community diagnostic centres are where capacity is growing fastest. They delivered 845,229 tests in August 2026, 22% more than in August 2025, and 8.77 million across 2025/26. National planning guidance expects their capacity to be fully used and their opening hours extended where possible. Whatever happens in elective surgery, there is clear demand for diagnostic throughput.

Yorkshire and the Humber: two markets in one region

On a commissioner basis, West Yorkshire ICB had 70.5% of pathways within 18 weeks in August 2026, well above England. Some 12.7% of its patients’ waiting pathways were held by non-NHS providers, almost double the national figure of 6.6%. Humber and North Yorkshire ICB had 60.5% within 18 weeks and 6,114 pathways over 52 weeks. That is 2.7% of its list, against 1.5% across all reporting providers. South Yorkshire figures are not comparable this month because Sheffield Teaching Hospitals did not submit data.

What this means

For independent providers, growth will not come from doing more of the same ophthalmology and orthopaedic volume. Activity plans are capping that. The opportunity is in specialties with long waits and little independent capacity, such as gynaecology, ENT and oral surgery, and in diagnostics, where demand is growing faster than activity. The case has to be made ICB by ICB, and it has to show value as well as speed.

For health technology companies, including overseas firms entering the UK, the data points to productivity rather than capacity. Admitted activity is falling while referrals rise, so tools that validate waiting lists, manage referral demand, move follow-ups to patient-initiated pathways or increase diagnostic throughput address the binding constraint. A national 70% target with flat surgical activity will be met through better use of capacity or not at all.

National averages are a poor guide to commercial decisions. Performance, long waits and independent sector penetration vary widely between neighbouring ICBs, even within one region. Providers should map their specialty mix against local waiting lists and contracting intentions before they set targets for 2027. Minshall Group’s DataLense healthcare commercial intelligence and market entry work are built for that kind of analysis.